AKT1 and gastrointestinal stromal tumor: Similarly, activation of PI3-kinase/AKT pathway was well-documented for GIST cell lines and patient samples and played an important role for was critical to survival in IM-resistant GIST [1,2,3,7], thereby illustrating a rationale for combination therapy (e.g., of imatinib mesylate and AKT inhibitor) for patients with GIST [8].